Comparison of the Indocyanine Green Fluorescence and Blue Dye Methods in Detection of Sentinel Lymph Nodes in Early-stage Breast Cancer

PurposeTo assess the diagnostic performance of sentinel lymph node (SLN) biopsy using the indocyanine green (ICG) fluorescence method compared with that using the blue dye method, a prospective multicenter study was performed.MethodsPatients with T1–3 primary breast cancer without clinical lymph node involvement were included in this study. ICG as a fluorescence-emitting source and indigo carmine as blue dye were injected into the subareolar area. Extracted lymph nodes were examined to identify the first, second, and other SLNs. The identified nodes were classified according to the ICG fluorescence signal and blue dye uptake.ResultsNinety-nine eligible patients were included in this study. The ICG fluorescence method identified an average of 3.4 SLNs (range, 1–8) in 98 of 99 patients (detection rate, 99 %). The number of lymph nodes identified by the fluorescence method was significantly higher than that identified by the blue dye method (p < 0.001). SLN involvement was identified in 20 % (20 of 99) of patients, all of whom tested positive for the first SLN. In 16 patients, complete axillary lymph node dissection (ALND) was performed. In 25 % (4 of 16) of these patients, axillary metastases were identified; however, no axillary involvement was found in 8 patients with only one involved node, which was isolated as the first SLN.ConclusionsHigh rate of SLN detection was achieved using the ICG fluorescence method. The first SLN identified by fluorescence imaging provides an exact indication of the axillary status. Therefore, the ICG fluorescence method provides precise information required to avoid unnecessary ALND.

[1]  T. Julian,et al.  Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. , 2010, The Lancet. Oncology.

[2]  Andreas Shamiyeh,et al.  Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma , 2000, Cancer.

[3]  G. Anderson,et al.  Obesity and the Risk for Premenopausal and Postmenopausal Breast Cancer , 2012, Cancer Prevention Research.

[4]  S Noguchi,et al.  Sentinel node biopsy guided by indocyanine green dye in breast cancer patients. , 1999, Japanese journal of clinical oncology.

[5]  A. Rademaker,et al.  Learning sentinel node biopsy: results of a prospective randomized trial of two techniques. , 1999, Surgery.

[6]  M. J. Kennedy,et al.  Obesity Increases the Risk of Postmenopausal Breast Cancer and is Associated with More Advanced Stage at Presentation But no Impact on Survival , 2010, The breast journal.

[7]  D L Morton,et al.  Technical details of intraoperative lymphatic mapping for early stage melanoma. , 1992, Archives of surgery.

[8]  L. Newman,et al.  Sentinel lymph node biopsy for breast cancer: How many nodes are enough? , 2007, Journal of surgical oncology.

[9]  Masakazu Toi,et al.  A Novel Method for Sentinel Lymph Node Biopsy by Indocyanine Green Fluorescence Technique in Breast Cancer , 2010, Cancers.

[10]  U. Chetty,et al.  Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. , 2006, Journal of the National Cancer Institute.

[11]  Mark C Kelley,et al.  Lymphatic mapping and sentinel lymphadenectomy for breast cancer. , 2004, American journal of surgery.

[12]  A E Giuliano,et al.  Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Murawa,et al.  Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence , 2009, The British journal of surgery.

[14]  L. Tafra,et al.  Multicenter Trial of Sentinel Node Biopsy for Breast Cancer Using Both Technetium Sulfur Colloid and Isosulfan Blue Dye , 2001, Annals of surgery.

[15]  Aya Nakagawa,et al.  Intraoperative identification of sentinel lymph nodes by near-infrared fluorescence imaging in patients with breast cancer. , 2008, American journal of surgery.

[16]  A. Giuliano,et al.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.

[17]  S. Noguchi,et al.  Sentinel Node Biopsy Guided by Indocyanin Green Dye in Breast Cancer Patients , 1999 .

[18]  Mitsuharu Miwa,et al.  Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer , 2005, Breast cancer.

[19]  S. Duffy,et al.  Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Umberto Veronesi,et al.  A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. , 2003, The New England journal of medicine.

[21]  P B Cerrito,et al.  Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  E. Winer,et al.  Identifying Gaps in the Locoregional Management of Early Breast Cancer: Highlights from the Kyoto Consensus Conference , 2011, Annals of Surgical Oncology.

[23]  D. Weaver,et al.  Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. , 1993, Surgical oncology.

[24]  Takayuki Kinoshita,et al.  Evaluation of sentinel node biopsy by combined fluorescent and dye method and lymph flow for breast cancer. , 2010, Breast.

[25]  Gary H Lyman,et al.  Lymphatic mapping and sentinel lymph node biopsy in early‐stage breast carcinoma , 2006, Cancer.

[26]  Seho Park,et al.  How Many Sentinel Lymph Nodes Are Enough for Accurate Axillary Staging in T1-2 Breast Cancer? , 2011, Journal of breast cancer.

[27]  M. Kawashima,et al.  Transcutaneous detection and direct approach to the sentinel node using axillary compression technique in ICG fluorescence-navigated sentinel node biopsy for breast cancer , 2012, Breast Cancer.

[28]  M. Mazumdar,et al.  Complementarity of Blue Dye and Isotope in Sentinel Node Localization for Breast Cancer: Univariate and Multivariate Analysis of 966 Procedures , 2001, Annals of Surgical Oncology.

[29]  M. Hughes,et al.  Obesity and lymphatic mapping with sentinel lymph node biopsy in breast cancer. , 2004, American journal of surgery.

[30]  D. Reintgen,et al.  Age and Body Mass Index May Increase the Chance of Failure in Sentinel Lymph Node Biopsy for Women with Breast Cancer , 2002, The breast journal.

[31]  G. Wishart,et al.  A feasibility study (ICG-10) of indocyanine green (ICG) fluorescence mapping for sentinel lymph node detection in early breast cancer. , 2012, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[32]  Michael Hünerbein,et al.  ICG fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer , 2010, Breast Cancer Research and Treatment.